Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) EPS (Weighted Average and Diluted) (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.36 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 5.26% to -$0.36 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.6, a 4.58% decrease, with the full-year FY2024 number at -$1.63, down 55.24% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.36 for Q3 2025 at Werewolf Therapeutics, up from -$0.4 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $5.97 in Q3 2021 to a low of -$83.36 in Q1 2021.
  • A 5-year average of -$4.53 and a median of -$0.39 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 99.33% in 2022, then crashed 186.67% in 2024.
  • Werewolf Therapeutics' EPS (Weighted Average and Diluted) stood at $0.95 in 2021, then plummeted by 140.0% to -$0.38 in 2022, then rose by 13.16% to -$0.33 in 2023, then plummeted by 33.33% to -$0.44 in 2024, then rose by 18.18% to -$0.36 in 2025.
  • Per Business Quant, the three most recent readings for HOWL's EPS (Weighted Average and Diluted) are -$0.36 (Q3 2025), -$0.4 (Q2 2025), and -$0.4 (Q1 2025).